Prostate Cancer ‘Dream Teams’ Lay Out Project Plans to Target Treatment-Resistant Prostate Cancer and to Identify New Prostate Cancer Subgroups

Last week, cancer researchers gathered in Washington, D.C., to attend the American Association for Cancer Research (AACR) annual meeting. At the meeting, two large-scale projects to improve the treatment of prostate cancer and prolong patients’ survival were outlined in presentations by two prominent researchers and clinicians: Arul M. Chinnaiyan, MD, PhD, a professor of urology at the University of Michigan and director of the Michigan Center for Translational Pathology in Ann Arbor, Michigan, and Eric J. Small, MD, the deputy director of clinical sciences at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. Continue reading…

Prostate Cancer Foundation and Sanofi Start Text Message Support Program for Men with Advanced Prostate Cancer

The Prostate Cancer Foundation (PCF) has joined with pharmaceutical company Sanofi to start a text message-based support program for men in the U.S. undergoing chemotherapy for advanced prostate cancer. The program, Prost8Care, is meant to provide patients with encouragement and education during a 12-week treatment course. To learn more, and to sign up, click here.

Work-Related Stress Unlikely to Cause Prostate Cancer

Researchers at the Finnish Institute of Occupational Health and University College London have conducted a meta-analysis of 12 studies to determine if job strain is related to cancer risk. Their findings suggest there is no relationship between work-related stress and overall cancer risk.

In the UK, Rate of Prostate Cancer Diagnoses Increase as Deaths from the Disease Decrease

Cancer Research UK has released figures indicating that the number of prostate cancer cases diagnosed yearly have tripled over the last 20 years. In contrast, the number of deaths from the disease have decreased by 18%. Experts suggest the increase in diagnoses is due to widespread use of PSA (prostate-specific antigen) testing and the decrease in deaths is because of earlier diagnosis and improved treatments.